BIAsp50与BHI50治疗2型糖尿病疗效及其对患者2hPG、sICAM-1、sVCAM-1、MCP-1和TNF-α的影响

doi:10.3969/j.issn.1671-7171.2018.03.013

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To study the effect of biphasic insulin aspart 50 (BIAsp50) and biphasic human insulin 50 (BHI50) in type 2 diabetes mellitus (T2DM) and on 2h postprandial plasma glucose (2hPG), serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule (sVCAM-1), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α).【Methods】66 patients with T2DM without previous insulin treatment in our hospital from January 2016 to January 2017 were enrolled the study and randomly divided into BIAsp50 group and BHI50 group, 33 cases in each group. Patients in the two groups were given BIAsp50 and BHIsp50 through subcutaneous injection twice daily. Fasting plasma glucose (FPG), 2hPG and its increment, incremental area under curve (IAUC) within postprandial 2h, serum levels of inflammatory markers including sICAM-1, sVCAM-1, MCP-1 and TNF-α were compared between the two groups before and after treatment.【Results】⑴There were no significant differences in baseline data, plamsa glucose level and inflammation markers between the two groups before treatment (P>0.05). ⑵ At 6 and 12 weeks after treatment, plasma glucose level were significantly decreased in the two groups (P<0.05).There was no significant difference in FPG between the two groups after treatment (P>0.05). 2hPG and its increment, IAUC within postprandial 2h in the BIAsp50 group at 6 and 12 weeks after treatment were significantly lower than those in BHI50 group, and HbA1c at 12 weeks after treatment was significantly lower than that in the BHI50 group (P<0.05). ⑶The total incidence of hypoglycemia in the BIAsp50 group was 12.1% and significantly lower than in the BHI50 group 33.3% (P<0.05), but there were no significant differences in incidences of each type of hypoglycemia between the two groups (P>0.05). ⑷At 6 and 12 weeks after treatment, serum levels of inflammatory markers were significantly decreased in the two groups (P<0.05). Serum levels of inflammatory markers in the BIAsp50 group at 6 and 12 weeks after treatment were significantly lower than those in the BHI50 group, and sICAM-1, MCP-1 at 12 weeks after treatment were significantly lower than those in the BHI50 group (P<0.05).【Conclusion】Compared with BHI50, BIAsp50 has better control effect on postprandial plasma glucose in patients with T2DM, and can decrease the incidence of hypoglycemia, and serum levels of sICAM-1, sVCAM-1, MCP-1 and TNF-α were lower, thus the improvement of injury of vascular endothelial cells and inflammation response is more prominent.

Key words： Diabetes Mellitus, Type 2/DT Insulin/PD Insulin/AA Postprandial Period Blood Glucose/ME Cell Adhesion Molecules/DE Chemokine CCL2/DE

Received: 05 December 2017

PACS:

R587.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2018.03.013 OR http://www.jcr.net.cn/EN/Y2018/V35/I3/459

[1] Yang W,Lu J,Weng J,et al.Prevalence of diabetes among men and women in China[J].N Engl J Med,2010,362 (12):1090-1101.
[2] 韦瑛瑛,刘潇,俞柳萍,等.65岁以上2型糖尿病患者的诊治及预防[J].转化医学电子杂志,2016,3(7):94-95.
[3] 潘长玉,纪立农,陆菊明,等.2型糖尿病患者起始地特胰岛素治疗时的临床基线情况SOLVETM国际研究中国亚组结果[J].中华内科杂志,2012,51(12):957-961.
[4] 王南楠,魏东,黄斌,等.短期持续皮下胰岛素输注强化治疗对2型糖尿病患者血尿酸、血脂、血清γ-谷氨酰转肽酶水平的影响[J].中国医学前沿杂志(电子版),2016,8(5):103-106.
[5] Ji LN,Lu JM,Guo XH,et al.Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables [J].BMC Public Health,2013,13:602.
[6] 郭晓蕙,边芳,董玉梅,等.双时相门冬胰岛素50与人胰岛素50的疗效和安全性比较:一项随机交叉试验[J].中华内分泌代谢杂志,2016,32(7):564-571.
[7] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[M].北京:北京大学医学出版社,2011:5.
[8] Seaquist ER,Anderson J,Childs B,et al.Hypoglycemia and diabetes:a report of a workgroup of the American Diabetes Association and the Endocrine Society [J].Diabetes Care,2013,36 (5):1384-1395.
[9] 吴珮毓.双相门冬胰岛素治疗2型糖尿病的疗效和安全性观察[D].重庆医科大学,2011.
[10] Nobels F,D'Hooge D,Crenier L.Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice:observational study results [J].Curr Med Res Opin,2012,28(6):1017-1026.
[11] Barendse S,Singh H,Frier BM,et al.The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type2 diabetes:a narrative review[J].Diabet Med,2012,29 (3):293-302.
[12] Frier BM.Hypoglycaemia in diabetes mellitus:epidemiology and clinical implications[J].Nat Rev Endocrinol,2014,10:711-722.
[13] 杨鹏飞.2型糖尿病患者内皮依赖性血管舒张功能、sICAM-1的变化及胰岛素泵强化治疗对其的作用[D].山西医科大学,2011.
[14] 宿建丽.2型糖尿病患者血清TNF-α、Leptin、sVCAM-1水平与心脑血管并发症相关性研究[D].青岛大学,2013.
[15] 赵永才,李新胜,张金成,等.糖耐量异常或2型糖尿病患者血清sVCAM-1影响因素探讨[J].中国医药导刊,2011,13(4):666-667.
[16] 葛欣联.血清25羟基维生素D3及MCP-1水平与2型糖尿病及颈动脉粥样硬化的关系研究[D].河北医科大学,2014.
[17] 徐海波,闫晓光,钟威,等.新诊断2型糖尿病患者血清Nesfatin-1、肿瘤坏死因子-α水平与胰岛素抵抗的相关性研究[J].中国糖尿病杂志,2017,25(1):45-48.